Qualicorp Consulting and Insurance Brokerage (QUAL3) Q2 2024 earnings summary

Executive summary

• The company faced a challenging healthcare market in Q2 2024, with high loss ratios and significant portfolio cancellations, but demonstrated resilience through operational efficiency, commercial realignment, and a focus on sustainable product offerings.

• Net revenue for Q2 2024 was R$398.8 million, down 8.3% year-over-year, mainly due to a 26% drop in the managed lives base from HMO cancellations, partially offset by higher agency income.

• Adjusted EBITDA margin reached 45.4% in Q2 2024, with adjusted EBITDA of R$181.0 million; Adjusted EBITDA-CAC margin was 38.3%, the highest in three years.

• The company completed a R$200 million debenture issuance, paid R$550 million in principal and R$137 million in interest on previous debentures, and recognized a R$43.5 million provision for a leniency agreement.

• Free cash flow in Q2 2024 was R$129.2 million, up 16.4% sequentially, supported by operational efficiency and a one-off receipt from the sale of Qsaúde.

Financial highlights

• Managed portfolio ended Q2 2024 with 688.9k members, down 8.6% sequentially and 25.8% year-over-year.

• Net revenue for 1H24 was R$802.4 million, down 8.3% year-over-year.

• Adjusted EBITDA for 1H24 was R$369.6 million, down 8.8% year-over-year, with a margin of 46.1%.

• Adjusted net income for 1H24 was R$49.0 million, up 44.3% year-over-year; Q2 adjusted net income was R$30.1 million, up 59.0% sequentially and 112.4% year-over-year.

• Net debt at Q2 2024 was R$1.10 billion, with leverage at 1.48x LTM Adjusted EBITDA.

Outlook and guidance

• The company expects continued improvement in loss ratios and operational efficiency, with a focus on sustainable product portfolios, commercial realignment, and further deleveraging.

• 78 new products were launched in 2024, with 13 new payors (5 partnerships signed, 8 in negotiation), aiming for greater sustainability and member retention.